NCT06991257

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AN ORAL BRANCHED-CHAIN KETOACID DEHYDROGENASE KINASE INHIBITOR, PF-07328948, IN ADULTS WITH HEART FAILURE (BRANCH-HF)

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 620 (estimated)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 79 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to learn about the safety and effects of the study medicine (PF-07328948) for the possible treatment of heart failure (HF).

Detailed description

All participants in this study will take either the study medicine (PF-07328948) tablets, or placebo tablets, once daily, by mouth, every day for 36 weeks. The study determines if the study medicine (PF-07328948) is safe and effective compared to placebo in people with heart failure who are already taking standard-of-care medications for heart failure that include sodium-glucose cotransporter 2 (SGLT2) inhibitors. Participants will be involved in this study for about 48 weeks. During this time, participants will visit the study clinic 15 times. In general, 5 of these visits may be performed at home by phone and the other 10 visits will take place at the study site.

Conditions

• Heart Failure

Interventions

Type	Name	Description
DRUG	Placebo	ARM 1
DRUG	Low Dose PF-07328948	ARM 2
DRUG	Medium Dose PF-07328948	ARM 3
DRUG	High Dose PF-07328948	ARM 4

Timeline

• Start date: 2025-06-19
• Primary completion: 2027-11-16
• Completion: 2027-12-14
• First posted: 2025-05-27
• Last updated: 2026-04-14

Locations

132 sites across 13 countries: United States, Brazil, Bulgaria, Canada, China, Czechia, France, Hungary, Japan, Poland, Puerto Rico, Spain, United Kingdom

Regulatory

• FDA-regulated drug study